OncoMatch/Clinical Trials/NCT06138990
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Is NCT06138990 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Clinical standard-of-care (physician's choice) for aml, adult.
Treatment: Clinical standard-of-care (physician's choice) — With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: PML fusion with RARA
Acute promyelocytic leukemia (APL) with PML-RARA
Prior therapy
Cannot have received: investigational drug
Participation in a clinical trial with an investigational drug within the 30 days preceding and during the present investigation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify